-
Posted: October 14th, 2024, 11:00pm UTC
Conditions: Urachal Cancer; Parathyroid Carcinoma; Fibrolamellar Carcinoma; Angiosarcoma; Secretory Carcinoma of Breast; Anal Neoplasms; Metaplastic Breast Carcinoma; Translocation Renal Cell Carcinoma; Carcinosarcoma; Small Intestine Neoplasms; Cholangiocarcinoma; Sertoli-Leydig Cell Tumor; Adenoid Cystic Carcinoma; Mesothelioma; Neuroblastoma; Adrenal Gland Neoplasms; Penile Neoplasms; Apocrine Carcinoma; Fibrosarcoma; Cancer of Unknown Primary; Hemangioblastoma; Thyroid Neoplasms; Hepatoblastoma; Fallopian Tube Neoplasms; Leiomyosarcoma; Vaginal Neoplasms; Neurofibrosarcoma; Gallbladder Neoplasms; Osteosarcoma; Biliary Tract Neoplasms; Clear Cell Endometrial Cancer; Yolk Sac Tumor; Vulvar Neoplasms; Kaposi Sarcoma; Ovarian Epithelial Cancer; Soft Tissue Sarcoma; Urethral Neoplasms; Granulosa Cell Tumor; Primitive Neuroectodermal Tumor; Neuroendocrine Tumors; Trophoblastic Tumor
Interventions: Drug: Nivolumab
Sponsors: Instituto do Cancer do Estado de São Paulo; Financiadora de Estudos e Projetos
Recruiting
-
Posted: October 10th, 2024, 11:00pm UTC
Conditions: Thoracic Cancer; Head and Neck Cancer; Pelvic Cancer; Hepatobiliary Carcinoma in Situ; Retroperitoneal Cancer; Distributed and Orphan Tumors
Interventions: Device: RefleXion X1 Radiotherapy System [Imaging Only]
Sponsors: RefleXion Medical
Not yet recruiting
-
Posted: October 8th, 2024, 11:00pm UTC
Conditions: Hepatopancreaticobiliary (HPB) Malignancy; Gall Bladder Cancer; Bile Duct Cancer; Pancreatoduodenectomy; Hepatectomy
Interventions: Other: Hepatopancreatoduodenectomy
Sponsors: Seoul National University Hospital
Completed
-
Posted: October 2nd, 2024, 11:00pm UTC
Conditions: Liver Neoplasms
Sponsors: Sun Yat-sen University
Not yet recruiting
-
Posted: October 1st, 2024, 11:00pm UTC
Conditions: Biliary Tract Cancer (BTC)
Interventions: Drug: D07001-Softgel Capsules; Drug: Placebo; Combination Product: Capecitabine
Sponsors: InnoPharmax Inc.
Not yet recruiting
-
Posted: September 26th, 2024, 11:00pm UTC
Conditions: Biliary Strictures
Interventions: Device: EUS-FNB
Sponsors: Ospedali Riuniti di Foggia
Recruiting
-
Posted: September 26th, 2024, 11:00pm UTC
Conditions: Malignant Hilar Stricture
Interventions: Procedure: ERCP biliary drainage; Procedure: Combined ERCP and EUS-HGS biliary drainage
Sponsors: Mansoura University
Recruiting
-
Posted: September 23rd, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma Cancer; Adebrelimab (SHR-1316)
Interventions: Drug: Adebrelimab and capecitabine; Drug: capecitabine
Sponsors: The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting
-
Posted: September 23rd, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Sponsors: iOMEDICO AG; Servier Deutschland GmbH
Not yet recruiting
-
Posted: September 23rd, 2024, 11:00pm UTC
Conditions: Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumor; Metastatic Solid Tumor
Interventions: Drug: LY4066434.; Drug: Cetuximab; Drug: Nab paclitaxel; Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Leucovorin; Drug: Irinotecan; Drug: 5Fluorouracil; Drug: Carboplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Pembrolizumab
Sponsors: Eli Lilly and Company
Not yet recruiting
-
Posted: September 19th, 2024, 11:00pm UTC
Conditions: Hepatocellular Carcinoma
Interventions: Combination Product: TACE, Lenvatinib, combined with Tislelizumab group
Sponsors: Fujian Provincial Hospital
Recruiting
-
Posted: September 4th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: HNF4α srRNA
Sponsors: Shanghai Changzheng Hospital
Not yet recruiting
-
Posted: September 2nd, 2024, 11:00pm UTC
Conditions: Chronic Pancreatitis; Pancreatic Exocrine Insufficiency
Interventions: Behavioral: Phone-based PERT education intervention
Sponsors: Changhai Hospital
Recruiting
-
Posted: August 27th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Genetic: Injection of CD-801, a lipid nanoparticle-encapsulated self-replicating RNA encoding hepatocyte nuclear factor 4α (HNF4α)
Sponsors: Shanghai Changzheng Hospital
Not yet recruiting
-
Posted: August 26th, 2024, 11:00pm UTC
Conditions: Pancreatic Cancer; Cholangiocarcinoma; Intraductal Papillary Mucinous Neoplasm; Neuroendocrine Tumor; Solid Pseudopapillary Tumor
Interventions: Dietary Supplement: oral protein supplements; Genetic: placebo
Sponsors: Yonsei University
Completed
-
Posted: August 26th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma Resectable
Interventions: Drug: Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig
Sponsors: University Health Network, Toronto; Sunnybrook Health Sciences Centre; Hamilton Health Sciences Corporation
Not yet recruiting
-
Posted: August 22nd, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma; Chemotherapy Effect; Immunotherapy
Interventions: Drug: Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody
Sponsors: Third Affiliated Hospital, Sun Yat-Sen University; Second Affiliated Hospital of Guangzhou Medical University
Not yet recruiting
-
Posted: August 7th, 2024, 11:00pm UTC
Conditions: Hepatocholangiocarcinoma; Fibrolamellar Carcinoma; Hepatic Epithelioid Hemangioendothelioma; Hepatoblastoma; Hepatic Neuroendocrine Carcinoma; Hepatic Carcinosarcomas; Hepatic Cystadenoma; Hepatic Leiomyosarcomas; Hepatic Angiosarcomas; Cholangiocarcinoma
Sponsors: Federation Francophone de Cancerologie Digestive; Société Nationale Française de Gastroentérologie
Recruiting
-
Posted: August 6th, 2024, 11:00pm UTC
Conditions: Living Donor Liver Transplantation; Liver Transplantation; Neoadjuvant Therapy
Interventions: Procedure: Living donor liver transplantation
Sponsors: Jena University Hospital
Not yet recruiting
-
Posted: August 2nd, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma Patients
Interventions: Diagnostic Test: Endoscopic ultrasound-guided fine-needle aspiration
Sponsors: Asian Institute of Gastroenterology, India
Not yet recruiting
-
Posted: July 31st, 2024, 11:00pm UTC
Conditions: Biliary Tract Carcinoma; Cholangiocarcinoma
Interventions: Drug: Pemigatinib and Durvalumab
Sponsors: Eastern Hepatobiliary Surgery Hospital
Not yet recruiting
-
Posted: July 31st, 2024, 11:00pm UTC
Conditions: Biliary Tract Cancer
Interventions: Drug: Ivonescimab; Drug: FOLFOX regimen
Sponsors: UNICANCER; Cancer Research UK & UCL Cancer Trials Centre; Belgian Group of Digestive Oncology; Summit Therapeutics
Not yet recruiting
-
Posted: July 29th, 2024, 11:00pm UTC
Conditions: Resectable Hepatocellular Carcinoma; Macrovascular Invasion; CNLC IIIA Stage
Interventions: Drug: Neoadjuvant SBRT combined with Lenvatinib and Pucotenlimab
Sponsors: Sun Yat-sen University
Active, not recruiting
-
Posted: July 25th, 2024, 11:00pm UTC
Conditions: Advanced Solid Tumor
Interventions: Drug: Neratinib tablets
Sponsors: Convalife (Shanghai) Co., Ltd.
Not yet recruiting
-
Posted: July 18th, 2024, 11:00pm UTC
Conditions: Advanced/Metastatic Cancer
Interventions: Drug: futibatinib; Drug: futibatinib, fulvestrant
Sponsors: Taiho Oncology, Inc.
Enrolling by invitation
-
Posted: July 17th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Gemcitabine-Oxaliplatin Regimen
Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting
-
Posted: July 16th, 2024, 11:00pm UTC
Conditions: Pancreatic Ductal Adenocarcinoma; Cholangiocarcinoma; Gastric Cancer; Bladder Cancer; Hepatocellular Carcinoma; Pheochromocytoma; Ovarian Cancer
Interventions: Drug: [18F]FAPI-74; Drug: [18F]FDG
Sponsors: National Cancer Institute (NCI)
Not yet recruiting
-
Posted: July 15th, 2024, 11:00pm UTC
Conditions: Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Interventions: Drug: Ivosidenib; Drug: Durvalumab (for the first 8, 21-day, cycles); Drug: Gemcitabine (for the first 8, 21-day, cycles); Drug: Cisplatin (for the first 8, 21-day, cycles); Drug: Durvalumab (starting from cycle 9); Drug: Ivosidenib Recommended Combination Dose (RCD)
Sponsors: Institut de Recherches Internationales Servier
Not yet recruiting
-
Posted: July 15th, 2024, 11:00pm UTC
Conditions: Biliary Tract Cancer
Interventions: Radiation: Consolidative radiotherapy; Drug: Standard-of-care systemic therapy: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab
Sponsors: Shanghai Zhongshan Hospital
Not yet recruiting
-
Posted: July 10th, 2024, 11:00pm UTC
Conditions: Klatskin Tumor
Interventions: Radiation: Stereotactic body radiation therapy
Sponsors: Erasmus Medical Center; Dutch Cancer Society
Recruiting
-
Posted: July 8th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma; Chemotherapy Effect; Immunotherapy
Interventions: Drug: OBI-833/OBI-821
Sponsors: Chang Gung Memorial Hospital
Not yet recruiting
-
Posted: July 4th, 2024, 11:00pm UTC
Conditions: Hepatocellular Carcinoma Non-resectable; Cholangiocarcinoma Non-resectable; Liver Metastases; Liver Malignant Tumors
Interventions: Procedure: TACE with ICI
Sponsors: Tianjin Medical University Cancer Institute and Hospital
Recruiting
-
Posted: July 1st, 2024, 11:00pm UTC
Conditions: Cholecystectomy; Adults; Gall Stone; Polyps; Pancreatitis Biliary; Gallbladder Dyskinesia; Cholecystitis
Sponsors: University of Oran 1
Not yet recruiting
-
Posted: June 26th, 2024, 11:00pm UTC
Conditions: Carcinoma
Sponsors: Institute of Liver and Biliary Sciences, India
Recruiting
-
Posted: June 25th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Other: Non-Interventional Study
Sponsors: Mayo Clinic
Enrolling by invitation
-
Posted: June 21st, 2024, 11:00pm UTC
Conditions: Solid Tumor
Interventions: Drug: LB1410; Drug: LB4330
Sponsors: L & L biopharma Co., Ltd., Shanghai China; Shanghai East Hospital
Recruiting
-
Posted: June 17th, 2024, 11:00pm UTC
Conditions: Overall Survival; Disease-free Survival
Interventions: Procedure: Microwave ablation (MWA) versus Liver Resection (LR)
Sponsors: Chinese PLA General Hospital
Recruiting
-
Posted: June 11th, 2024, 11:00pm UTC
Conditions: Pancreatic Cancer Non-resectable; Bile Duct Cancer; Papillary Carcinoma; Duodenal Cancer
Interventions: Procedure: Randomization to uncovered SEMS treating jaundice due to distal malignant biliary obstruction.; Procedure: Randomization to partially covered SEMS treating jaundice due to distal malignant biliary obstruction.; Procedure: Randomization to fully covered SEMS treating jaundice due to distal malignant biliary obstruction.
Sponsors: Region Stockholm
Recruiting
-
Posted: June 7th, 2024, 11:00pm UTC
Conditions: ICC
Interventions: Radiation: radiotherapy; Drug: gemcitabine + cisplatin; Drug: slulimumab
Sponsors: Shanghai Zhongshan Hospital
Not yet recruiting
-
Posted: June 6th, 2024, 11:00pm UTC
Conditions: Primary Biliary Cholangitis
Sponsors: Ipsen
Recruiting
-
Posted: June 4th, 2024, 11:00pm UTC
Conditions: Extrahepatic Cholangiocarcinoma; Unresectable Perihilar or Ductal CCA
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Durvalumab; Procedure: ID-RFA
Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Universitätsklinikum Düsseldorf, Germany; Universitätsklinikum Köln, Germany; AstraZeneca
Recruiting
-
Posted: June 4th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Drug: Durvalumab; Drug: Olaparib
Sponsors: Australasian Gastro-Intestinal Trials Group; Wayne Elphinstone Research Fund; AstraZeneca
Not yet recruiting
-
Posted: June 3rd, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Combination Product: Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil
Sponsors: West China Hospital
Not yet recruiting
-
Posted: June 3rd, 2024, 11:00pm UTC
Conditions: Lung Cancer; Gastric Cancer; Liver Cancer; Colorectal Cancer; Pancreatic Cancer; Esophageal Cancer; Breast Cancer; Cervical Cancer; Ovarian Cancer; Endometrial Cancer; Bladder Cancer; Prostate Cancer; Cholangiocarcinoma
Sponsors: Singlera Genomics Inc.; Fudan University; Hubei Cancer Hospital, Huazhong University of Science and Technology; China-Japan Friendship Hospital; Shanxi Provincial Cancer Hospital; Xuhui Central Hospital, Fudan University; Shanghai Electric Power Hospital; East Hospital, Tongji University; The First Affiliated Hospital of Xi' an Jiaotong University; GaoZhou People's Hosipital; Anhui Provincial Hospital; Beijing Friendship Hospital
Not yet recruiting
-
Posted: June 3rd, 2024, 11:00pm UTC
Conditions: Advanced Cholangiocarcinoma; FGFR2 Fusion
Interventions: Drug: Pemigatinib; Drug: Atezolizumab; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; Incyte Corporation; Genentech, Inc.
Not yet recruiting
-
Posted: May 30th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Radiation: Proton Beam Therapy; Drug: Concurrent oral capecitabine chemotherapy; Drug: Cisplatin & Gemcitabine intravenous chemotherapy; Procedure: Orthotropic Liver Transplant
Sponsors: The Christie NHS Foundation Trust; University College London Hospitals; University College, London; Royal Free Hospital NHS Foundation Trust
Not yet recruiting
-
Posted: May 29th, 2024, 11:00pm UTC
Conditions: Chronic Liver Disease and Cirrhosis; Chronic Liver Disease; Portal Hypertension
Interventions: Diagnostic Test: hepatomiR
Sponsors: Karl Landsteiner University of Health Sciences; University Hospital St. Pölten
Recruiting
-
Posted: May 23rd, 2024, 11:00pm UTC
Conditions: Pancreatitis, Chronic
Interventions: Drug: Tocilizumab 20 MG/ML [Actemra]; Drug: Sodium Chloride 0.9% Inj
Sponsors: Soren Schou Olesen; Aarhus University Hospital; University of Aarhus; Viborg Regional Hospital; Stanford University; Haukeland University Hospital
Recruiting
-
Posted: May 20th, 2024, 11:00pm UTC
Conditions: Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma; Refractory Cholangiocarcinoma; Stage III Hilar Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Hilar Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Heat Shock Factor 1 Pathway Inhibitor NXP800; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Procedure: Ultrasound-Guided Biopsy
Sponsors: Mayo Clinic
Recruiting
-
Posted: May 17th, 2024, 11:00pm UTC
Conditions: Congenital Biliary Dilatation; Choledochal Cyst
Interventions: Device: Three-dimensional visualization technology
Sponsors: Zhujiang Hospital
Recruiting
-
Posted: May 16th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Lenvatinib
Sponsors: Zhiyong Huang
Not yet recruiting
-
Posted: May 16th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Diagnostic Test: Proteomic profile
Sponsors: University Hospital, Bordeaux
Not yet recruiting
-
Posted: May 14th, 2024, 11:00pm UTC
Conditions: Pancreatic Head Neoplasm; Delayed Gastric Emptying; Post Operative Ileus; Whipple Procedure
Interventions: Procedure: pancreaticoduodenectomy
Sponsors: Baylor College of Medicine
Completed
-
Posted: May 9th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Combination Product: Neoantigen Vaccine plus Capecitabine
Sponsors: Yongyi Zeng
Not yet recruiting
-
Posted: May 8th, 2024, 11:00pm UTC
Conditions: Adebrelimab; Hepatocellular Carcinoma
Interventions: Drug: Adebrelimab
Sponsors: Tianjin Medical University Cancer Institute and Hospital
Recruiting
-
Posted: May 6th, 2024, 11:00pm UTC
Conditions: Colorectal Cancer; Cholangiocarcinoma; Appendiceal Adenocarcinoma; Pancreatic Adenocarcinoma; Gastric Adenocarcinoma; Endometrial Adenocarcinoma; Triple Negative Breast Cancer; Ovarian Cancer; Prostate Cancer
Interventions: Drug: APL-5125
Sponsors: Apollo Therapeutics Ltd
Recruiting
-
Posted: April 25th, 2024, 11:00pm UTC
Conditions: Bile Duct Adenocarcinoma Non-Resectable; HER2 Gene Mutation
Interventions: Drug: Disitamab Vedotin Plus Cadonilimab
Sponsors: Zhejiang Cancer Hospital
Recruiting
-
Posted: April 24th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma; Cholangiocarcinoma, Intrahepatic; Cholangiocarcinoma Resectable; Cholangiocarcinoma; Liver
Interventions: Diagnostic Test: LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)
Sponsors: City of Hope Medical Center
Recruiting
-
Posted: April 24th, 2024, 11:00pm UTC
Conditions: Pancreas Cancer; Pancreas Neoplasm; Pancreas Adenocarcinoma; Periampullary Cancer; Periampullary Carcinoma; Microbial Colonization
Interventions: Procedure: Pancreatic resection
Sponsors: St. Antonius Hospital
Not yet recruiting
-
Posted: April 19th, 2024, 11:00pm UTC
Conditions: Malignant Biliary Obstruction; Biliary Tract Neoplasms; Pancreatic Cancer Non-resectable
Interventions: Procedure: Endoscopic biliary drainage; Device: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS); Device: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)
Sponsors: Hospital Universitari de Bellvitge; Hospital ClÃnico Universitario de Valencia; Hospital General Universitario de Alicante; Hospital Mutua de Terrassa; Hospital Universitario Ramon y Cajal; Hospital General Universitario de Castellón; Complejo Hospitalario de Navarra; University Hospital Virgen de las Nieves; Hospital de Sant Pau; University of Salamanca; Complejo Hospitalario Universitario de Santiago; Complejo Hospitalario Universitario de Vigo
Not yet recruiting
-
Posted: April 19th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Radiation: radioembolization with Y-90; Drug: Durvalumab; Drug: Cisplatin; Drug: Gemcitabine
Sponsors: Francesco De Cobelli; Cardarelli Hospital; A.O. Ospedale Papa Giovanni XXIII; AOU Pisana, Pisa, Italy
Recruiting
-
Posted: April 19th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Adebrelimab
Sponsors: Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting
-
Posted: April 19th, 2024, 11:00pm UTC
Conditions: Malignant Biliary Obstruction; Pancreatic Cancer; Biliary Tract Neoplasms
Interventions: Procedure: Endoscopic biliary drainage; Device: Self-expandable metallic stent (SEMS); Device: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)
Sponsors: Hospital Universitari de Bellvitge; Hospital Mutua de Terrassa; Hospital ClÃnico Universitario de Valencia; Hospital General Universitario de Alicante; Hospital Universitario Ramon y Cajal; Hospital General Universitario de Castellón; Hospital Ãlvaro Cunqueiro; Complejo Hospitalario Universitario de Santiago; University Hospital Virgen de las Nieves; Complejo Hospitalario de Navarra; Hospital de Sant Pau; University of Salamanca
Not yet recruiting
-
Posted: April 19th, 2024, 11:00pm UTC
Conditions: Malignant Biliary Obstruction; Pancreatic Cancer Resectable; Biliary Tract Neoplasms
Interventions: Procedure: Endoscopic biliary drainage; Device: Self-expandable metallic stent (SEMS); Device: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)
Sponsors: Hospital Universitari de Bellvitge; Hospital Mutua de Terrassa; Hospital ClÃnico Universitario de Valencia; Hospital General Universitario de Alicante; Hospital Universitario Ramon y Cajal; Hospital General Universitario de Castellón; Hospital Ãlvaro Cunqueiro; Complejo Hospitalario Universitario de Santiago; University Hospital Virgen de las Nieves; Complejo Hospitalario de Navarra; Hospital de Sant Pau; University of Salamanca
Not yet recruiting
-
Posted: April 17th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Radiation: Radiotherapy; Drug: HAIC (GEMOX); Drug: Chemotherapy
Sponsors: Shandong Cancer Hospital and Institute
Recruiting
-
Posted: April 17th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Procedure: Resection/Ablation of tumor; Procedure: Palliative chemotherapy; Procedure: Neoadjuvant chemotherapy; Procedure: Stereotatic radiotherapy; Procedure: Best supportive care
Sponsors: Rigshospitalet, Denmark
Recruiting
-
Posted: April 17th, 2024, 11:00pm UTC
Conditions: Advanced Solid Tumors; Cholangiocarcinoma
Interventions: Drug: Tinengotinib
Sponsors: TransThera Sciences (Nanjing), Inc.
Available
-
Posted: April 17th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma; Biliary Stricture
Sponsors: Soonchunhyang University Hospital
Not yet recruiting
-
Posted: April 12th, 2024, 11:00pm UTC
Conditions: Each Endoscopic Intervention Using X-rays
Interventions: Procedure: ERCP; Procedure: endoscopic ultrasound; Procedure: gastroscopy; Procedure: Colonoscopy; Procedure: placement of a nasojejunal tube
Sponsors: Central Hospital, Nancy, France
Not yet recruiting
-
Posted: April 12th, 2024, 11:00pm UTC
Conditions: Lung Cancer; Breast Cancer; Colorectal Cancer; Thyroid Cancer; Gastric Cancer; Cervical Cancer; Liver Cancer; Pancreatic Cancer; Cholangiocarcinoma; Prostate Cancer; Esophageal Cancer; Ovarian Cancer; Renal Cell Carcinoma
Sponsors: Beijing Friendship Hospital
Recruiting
-
Posted: April 10th, 2024, 11:00pm UTC
Conditions: Adenocarcinoma; Neuroendocrine Tumors; Hepatocellular Carcinoma; Cholangiocarcinoma; Malignant Lymphoma; Metastasis; Chronic Pancreatitis; Autoimmune Pancreatitis
Interventions: Device: EchoTip AcuCore
Sponsors: Cook Research Incorporated
Recruiting
-
Posted: April 10th, 2024, 11:00pm UTC
Conditions: Perihilar Cholangiocarcinoma
Sponsors: Beijing Tsinghua Chang Gung Hospital
Completed
-
Posted: April 9th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Drug: [18F]F-FAPI PET-CT
Sponsors: Mara Veenstra, MD; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); UMC Utrecht
Not yet recruiting
-
Posted: April 8th, 2024, 11:00pm UTC
Conditions: Ulcerative Colitis; Primary Sclerosing Cholangitis
Interventions: Dietary Supplement: Bromlein; Other: Placebo
Sponsors: National Nutrition and Food Technology Institute
Recruiting
-
Posted: April 2nd, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Drug: Durvalumab 1120 mg; Drug: Durvalumab 1500 mg; Drug: Tremelimumab i.v. at 300 mg; Combination Product: Cisplatin (CDDP) 25 mg/mq i.v; Combination Product: Gemcitabine (GEM) 1000 mg/mq i.v.
Sponsors: National Cancer Institute, Naples
Recruiting
-
Posted: April 2nd, 2024, 11:00pm UTC
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma; Primary Liver Cancer; Primary Liver Carcinoma; Hepatic Cancer; Hepatic Carcinoma
Interventions: Diagnostic Test: ELUCIDATE
Sponsors: City of Hope Medical Center
Recruiting
-
Posted: April 1st, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma; Multiple Myeloma; Colon Cancer; Rectal Cancer
Interventions: Other: Return of Genetic Results: Biomarker information from cancer cells; Other: Return of Genetic Results: Inherited mutations related to cancer; Other: Return of Genetic Results: Inherited mutations related to other medical issues
Sponsors: Washington University School of Medicine; National Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital
Recruiting
-
Posted: April 1st, 2024, 11:00pm UTC
Conditions: Pancreatic Disease; Pancreatic Cancer; Pancreatic Cyst; Gastrointestinal Tumor; Bile Duct Diseases; Bile Duct Cancer; Lymph Node Disease; Submucosal Tumor of Gastrointestinal Tract; Gastrointestinal Cancer
Interventions: Device: Endoscopic ultrasound examination
Sponsors: Orlando Health, Inc.
Recruiting
-
Posted: March 28th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: HAIC-GEMOX+Cadonilimab+Regorafenib
Sponsors: Fudan University
Recruiting
-
Posted: March 28th, 2024, 11:00pm UTC
Conditions: Solid Tumor
Interventions: Drug: ACTM-838
Sponsors: Actym Therapeutics, Inc.
Recruiting
-
Posted: March 22nd, 2024, 11:00pm UTC
Conditions: Primary Liver Cancer
Sponsors: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Recruiting
-
Posted: March 22nd, 2024, 11:00pm UTC
Conditions: Pharmacological Action
Interventions: Dietary Supplement: Virgin Coconut Oil
Sponsors: Food and Nutrition Research Institute, Philippines; Ateneo de Manila University; De La Salle Medical and Health Sciences Institute
Active, not recruiting
-
Posted: March 21st, 2024, 11:00pm UTC
Conditions: Pancreaticoduodenectomy
Interventions: Procedure: Main pancreatic duct and biliary duct external drainage; Procedure: Main pancreatic duct and biliary duct internal drainage
Sponsors: Shanghai Zhongshan Hospital; Huadong Hospital; RenJi Hospital; The First People's Hospital of Yunnan; First Affiliated Hospital Xi'an Jiaotong University; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Recruiting
-
Posted: March 15th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma; Chemotherapy Effect
Interventions: Drug: Floxuridine; Procedure: Selective Internal Radiation Therapy (SIRT)
Sponsors: Oslo University Hospital
Recruiting
-
Posted: March 15th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Surufatinibã€Toripalimabã€Gemcitabineã€Oxaliplatin
Sponsors: Fudan University
Not yet recruiting
-
Posted: March 12th, 2024, 11:00pm UTC
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Liver Metastases
Interventions: Procedure: Laparoscopic ablation; Procedure: Open ablation
Sponsors: Rigshospitalet, Denmark
Recruiting
-
Posted: March 12th, 2024, 11:00pm UTC
Conditions: Advanced Solid Tumor; Unresectable Solid Tumor; Metastatic Solid Tumor; Cholangiocarcinoma
Interventions: Drug: Afatinib; Drug: Pemigatinib
Sponsors: Massachusetts General Hospital; Boehringer Ingelheim; Incyte Corporation
Recruiting
-
Posted: March 8th, 2024, 1:00am UTC
Conditions: Duodenal Adenoma; Complication of Treatment
Interventions: Procedure: Stent Placement in Pancreatic and Bile Ducts
Sponsors: Beijing Friendship Hospital
Completed
-
Posted: March 7th, 2024, 1:00am UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab
Sponsors: Nanfang Hospital, Southern Medical University
Recruiting
-
Posted: March 6th, 2024, 1:00am UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Procedure: HAIC; Drug: Adebrelimab; Drug: Apatinib
Sponsors: Lei ZHAO
Recruiting
-
Posted: March 4th, 2024, 1:00am UTC
Conditions: Intrahepatic Cholangiocarcinoma; Machine Learning
Interventions: Procedure: lymph nodes dissection
Sponsors: West China Hospital
Recruiting
-
Posted: March 4th, 2024, 1:00am UTC
Conditions: Metastatic Colorectal Cancer; Pancreas Adenocarcinoma; Cholangiocarcinoma
Interventions: Diagnostic Test: Multiplex PCR-test for circulating tumor DNA
Sponsors: Oslo University Hospital
Recruiting
-
Posted: February 29th, 2024, 1:00am UTC
Conditions: Primary Sclerosing Cholangitis; Inflammatory Bowel Diseases
Interventions: Biological: Faecal Microbiota Transplant; Other: FMT Placebo
Sponsors: University of Birmingham; PSC Support; Life Arc
Recruiting
-
Posted: February 28th, 2024, 1:00am UTC
Conditions: Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence
Interventions: Drug: Adebrelimab, Apatinib, Gemcitabine, cisplatin
Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting
-
Posted: February 28th, 2024, 1:00am UTC
Conditions: Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)
Interventions: Drug: Allogeneic NK(CCT-ANK-11)
Sponsors: Beijing Kejing Biotechnology Co., Ltd.
Withdrawn
-
Posted: February 28th, 2024, 1:00am UTC
Conditions: Biliary Tract Cancer; HER2 Gene Mutation
Interventions: Drug: Zanidatamab; Drug: Cisplatin; Drug: Gemcitabine; Drug: Pembrolizumab; Drug: Durvalumab
Sponsors: Jazz Pharmaceuticals
Recruiting
-
Posted: February 26th, 2024, 1:00am UTC
Conditions: Biliary Stricture; Bile Duct Cancer; Pancreas Cancer
Sponsors: Peking University Third Hospital; Beijing Tsinghua Changgeng Hospital
Recruiting
-
Posted: February 23rd, 2024, 1:00am UTC
Conditions: Bile Duct Cancer
Interventions: Drug: Gemcitabin, Cisplatin and Durvalumab; Procedure: Biliary Radiofrequency Ablation; Procedure: Endoscopic Retrograde Cholangio-Pancreatography with stenting
Sponsors: Insel Gruppe AG, University Hospital Bern; Swiss Cancer League
Not yet recruiting
-
Fetched: February 21st, 2024, 3:01am UTC
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer; Intrahepatic Cholangiocarcinoma; Perihilar Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Hilar Cholangiocarcinoma; Distal Bile Duct Cancer
Interventions: Diagnostic Test: Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
Sponsors: University of Washington; Natera, Inc.; SEngine Precision Medicine, Inc.
Active, not recruiting
-
Posted: February 15th, 2024, 1:00am UTC
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Hepatobiliary Cancer
Interventions: Behavioral: Target Navigation Pilot Program
Sponsors: University of Miami; The V Foundation
Recruiting